Target Audience

This educational activity is intended for adult and pediatric providers caring for patients with atopic dermatitis.

Program Overview

This activity will inform and empower providers to optimize the treatment plan for patients with atopic dermatitis using precision medicine to improve their quality of life and outcomes

Learning Objectives

• Examine the patient-centric burden and clinical gravity of atopic dermatitis (AD), emphasizing the impact of itch and associated sleep interruption on health-related quality of life
• Identify the complex pathophysiology and heterogeneous clinical manifestations of AD, focusing on treatment implications and emerging pharmacologic targets
• Evaluate the evolving clinical trial evidentiary base for emerging biologic agents in treating AD, highlighting the therapeutic potential of targeting inflammatory and itch pathways
• Develop evidence-driven, individualized treatment plans for patients with moderate-to-severe AD that integrate novel monoclonal antibodies into the calculus

Faculty

Planning Committee

Jessica Martin, PhD, ELS, MWC
Medical Writer
Martin Medical Writing

Instructions for Participation and Credit

This activity will take approximately 60 minutes to complete. To receive credit, participants must complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 60% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or to generate the certificate.

CE Accreditation and Credit Designation Statement

The AAFP has reviewed The Evolving Era of Biologics to Improve Itching in Atopic Dermatitis and deemed it acceptable for up to 1.00 Enduring Materials, Self-Study AAFP Elective credit(s). Term of Approval is from 03/15/2024 to 03/15/2025. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners

Disclosure Policy

This program was planned in accordance with AANP CE Standards and Policies. All relevant financial relationships listed have been mitigated.

All Planners have no relevant financial relationships to disclose.

Faculty disclosures:

Leigh Ann Pansch

• Speaker Bureau: Abbvie, Pfizer, Sanofi-Regeneron (AD); Arcutis, BMS, Dermavant, Johnson & Johnson, Eli Lilly, UCB (PSO); Biersdorf (dry skin); Galderma (acne/rosacea); Novartis (HS); Eli Lilly (PSA/AA); Sanofi/Regeneron (PN); Johnson & Johnson (PSA)
• Consultant: Leo (AD)

Stephanie Simmerman

• Speaker Bureau: Abbvie, Dermavant, Arcutis (PSO), Sanofi-Regeneron (AD)
• Consultant: Heliocare (UV Light)

Disclaimer:

Individuals who have contributed to the CE Center were carefully selected for their knowledge and experience in the subject area under review. This presentation is informational only and may contain opinions of the authors from their personal experience that do not necessarily express the opinions of the American Association of Nurse Practitioners (AANP). The activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Clinical practice is a constantly changing process and new information becomes available every day. Neither AANP nor the contributing individuals can warrant that the material will continue to be accurate, nor do they warrant that the material is completely free of errors upon publication. Attendees and participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Commercial Support Acknowledgement

This activity is supported by an educational grant from Galderma